Kalvista Pharmaceuticals Inc (KALV:NASDAQ)
$27 0.01 (0.0371%)
Analysed Kalvista Pharmaceuticals Inc (KALV:NASDAQ) News Sources
Sector Update: Health Care Stocks Fall Late Afternoon
29-04-2026
yahoo.com
KalVista Scores $1.9 Billion Takeover Deal; Why A Key Rival Jumped Too
29-04-2026
yahoo.com
Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement
29-04-2026
fool.com
IBT portfolio manager says KalVista deal signals Biotech 2.0 growth
30-04-2026
yahoo.com
Chiesi widens rare disease portfolio with $1.9bn KalVista buyout
30-04-2026
pharmaceutical-technology.com
A Look At KalVista Pharmaceuticals (KALV) Valuation After A Strong Year Of Share Price Gains
10-05-2026
yahoo.com
KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema
28-05-2026
yahoo.com
KalVista's (KALV) Chief Development Officer Sells 33,800 Shares for $905,000
31-05-2026
fool.com
KalVista Pharmaceuticals (KALV) Upgraded to Buy: What Does It Mean for the Stock?
04-06-2026
yahoo.com
Chiesi Group Completes Acquisition of KalVista Pharmaceuticals
11-06-2026
yahoo.com
What is the current price of Kalvista Pharmaceuticals Inc (KALV:NASDAQ)?
The current price of Kalvista Pharmaceuticals Inc (KALV:NASDAQ) is $27.
Kalvista Pharmaceuticals Inc (KALV:NASDAQ) absolute price change since previous trading day?
The absolute price change of Kalvista Pharmaceuticals Inc (KALV:NASDAQ) since the previous trading day is $0.01.
Kalvista Pharmaceuticals Inc (KALV:NASDAQ) percentage price change since previous trading day?
The percentage price change of Kalvista Pharmaceuticals Inc (KALV:NASDAQ) since the previous trading day is 0.0371%.
What is the most recent average sentiment score for Kalvista Pharmaceuticals Inc (KALV:NASDAQ)?
The most recent average sentiment score for Kalvista Pharmaceuticals Inc (KALV:NASDAQ) is 86 out of 100.
What is the most recent average sentiment for Kalvista Pharmaceuticals Inc (KALV:NASDAQ)?
The most recent sentiment for Kalvista Pharmaceuticals Inc (KALV:NASDAQ) is .
SEC-8K** Filing Available For Kalvista Pharmaceuticals Inc (KALV:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.